Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue
Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy.
Pacific Biosciences Of California Inc. (PACB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 36,478,441 | $43,044,561 | +2% | 0.43% |
| 2. | Millennium Management Israel Englander | 2,204,044 | $2,600,772 | -88% | 0% |
| 3. | Rima Senvest Management Richard Mashaal | 1,093,954 | $1,290,866 | 0.05% | |
| 4. | Soros Fund Management George Soros | 1,000,000 | $1,180,000 | -58% | 0.02% |
| 5. | Hillhouse Capital Management Lei Zhang | 918,892 | $1,084,293 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.40 | 40,000 | $176,160.00 | 40,000 | 2024-03-06 | Filing | |
| $2.01 | 1 | $2.01 | 215,156 | 2018-09-01 | Filing | |
| $2.01 | 5,989 | $12,013.93 | 215,155 | 2018-03-01 | Filing | |
| $4.07 | 3,244 | $13,207.95 | 194,166 | 2017-09-01 | Filing | |
| $4.07 | 3,212 | $13,077.66 | 190,922 | 2017-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.00 | 5,195 | $5,200.20 | 269,259 | 2025-05-19 | Filing | |
| $1.41 | 12,497 | $17,583.28 | 2,225,357 | 2025-03-03 | Filing | |
| $1.41 | 6,486 | $9,125.80 | 1,497,695 | 2025-03-03 | Filing | |
| $1.41 | 2,973 | $4,183.01 | 184,619 | 2025-03-03 | Filing | |
| $1.88 | 24,349 | $45,727.42 | 187,592 | 2025-02-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 972,255 | $1,205,596 | 0.47% | |
| 2. | 563,670 | $698,951 | 0.11% | |
| 3. | 30,113 | $48,181 | 0% | |
| 4. | 27,517 | $34,121 | 0.01% | |
| 5. | 19,900 | $24,676 | 0.01% |
News See All
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript May 8, 2025Pacific Biosciences of California, Inc. beats earnings expectations.
10 Most Volatile Stocks Under $3 For Day Trading
Day trading involves buying and selling stocks within a single trading day to capitalize on short-term price movements.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript February 13, 2025Pacific Biosciences of California, Inc. beats earnings expectations.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
10 Worst ARK Stocks To Buy According to Short Sellers
Cathie Wood of ARK Investment is one of Wall Street's most well-known hedge fund bosses.
10 Best Genomics Stocks To Buy Right Now
Genomics is the study of genes and how they function.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Call Transcript November 7, 2024Pacific Biosciences of California, Inc. beats earnings expectations.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
Billionaire Hedge Funds
